Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 9c; Offers FY23 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $234.66 +2.14%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.84, $0.09 worse than the analyst estimate of $4.93. Revenue for the quarter came in at $972 million versus the consensus estimate of $969.02 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2023 EPS of $18.15-$19.00, versus the consensus of $18.66.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- National Fuel Gas (NFG) Tops Q4 EPS by 18c; offers guidance
- eHealth (EHTH) Misses Q3 EPS by 45c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
